Thorne HealthTech price target raised to $6 from $5.50 at Canaccord

Canaccord raised the firm’s price target on Thorne HealthTech to $6 from $5.50 and keeps a Buy rating on the shares. The analyst said as consumers increasingly take charge of their own health and wellness, we believe the company is well positioned to continue at its strong +20% top-line growth rate and expand its already healthy long-term EBITDA margins.